Latest news

• EMA hands UniQure orphan status first in Huntington's

  Its Huntington’s disease candidate, currently known as AMT-130, becomes the first investigational AAV-gene therapy in this disease area to receive the status. ... UniQure’s candidate fit the bill, not least because there are no currently approved

• Roche signs Parkinson's deal with Prothena

  Antibody development agreement is worth up to $600m. Roche has upped its efforts in Parkinson's disease by agreeing to research new antibodies with the US biotech Prothena. ... This technology was also a key aspect of a recent deal with Isis to tackle

• Roche and Isis in $392m deal to research drugs for brain disorder

  The unmet medical need for Huntingdon's disease is compounded by its severity, with patients enduring progressive loss of both mental faculties and physical control. ... foundation exclusively dedicated to the development of therapies that slow the

• Bouncing back

  The deal should speed up new treatments for Huntingdon's disease, Parkinson's disease and for strokes. ... attention to incidents of vision loss among patients taking GSK's Levitra, Pfizer's Viagra and Lilly's Cialis.

• Malcolm's Market Eye: 7 to 13 July 2007

  The market for ReNeuron's treatment is large with some 12m stroke survivors in Japan, the US and the EU, with nearly one third needing continual nursing care. ... ReNeuron is also focusing on inherited Huntingdon's disease and type 1 diabetes needing